BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26926447)

  • 1. Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.
    Karamchandani DM; Lehman HL; Ohanessian SE; Massé J; Welsh PA; Odze RD; Goldblum JR; Berg AS; Stairs DB
    Diagn Pathol; 2016 Feb; 11():23. PubMed ID: 26926447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
    Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
    Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
    Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
    World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Progression Prediction in Barrett's Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria.
    Ten Kate FJC; Nieboer D; Ten Kate FJW; Doukas M; Bruno MJ; Spaander MCW; Looijenga LHJ; Biermann K;
    Am J Surg Pathol; 2018 Jul; 42(7):918-926. PubMed ID: 29697438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopic Raman spectroscopy enables objective diagnosis of dysplasia in Barrett's esophagus.
    Almond LM; Hutchings J; Lloyd G; Barr H; Shepherd N; Day J; Stevens O; Sanders S; Wadley M; Stone N; Kendall C
    Gastrointest Endosc; 2014 Jan; 79(1):37-45. PubMed ID: 23886354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Darlavoix T; Seelentag W; Yan P; Bachmann A; Bosman FT
    Virchows Arch; 2009 Jun; 454(6):629-37. PubMed ID: 19396460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
    van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
    Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
    Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
    World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.
    Duits LC; Lao-Sirieix P; Wolf WA; O'Donovan M; Galeano-Dalmau N; Meijer SL; Offerhaus GJA; Redman J; Crawte J; Zeki S; Pouw RE; Chak A; Shaheen NJ; Bergman JJGHM; Fitzgerald RC
    Dis Esophagus; 2019 Jan; 32(1):. PubMed ID: 30496496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
    Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
    Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus.
    Vennalaganti P; Kanakadandi V; Goldblum JR; Mathur SC; Patil DT; Offerhaus GJ; Meijer SL; Vieth M; Odze RD; Shreyas S; Parasa S; Gupta N; Repici A; Bansal A; Mohammad T; Sharma P
    Gastroenterology; 2017 Feb; 152(3):564-570.e4. PubMed ID: 27818167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
    Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
    Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of confocal laser endomicroscopy in identifying high-grade dysplasia and adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
    Gupta A; Attar BM; Koduru P; Murali AR; Go BT; Agarwal R
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):369-77. PubMed ID: 24535597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological assessment & use of immunohistochemical markers for detection of dysplasia in Barrett's esophageal mucosa.
    Kinra P; Gahlot GPS; Yadav R; Baloda V; Makharia GK; Gupta SD; Das P
    Pathol Res Pract; 2018 Jul; 214(7):993-999. PubMed ID: 29764708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
    Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
    Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.